SEARCH

SEARCH BY CITATION

References

  • 1
    Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992; 15: 948963.
  • 2
    Colombo M, de Franchis R, Del Ninno E, Sangiovanni- A, De-Fazio- C, Tommasini- M. Donato -M-F, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675680.
  • 3
    Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, et al. A multivariate analysis of risk factors for hepatocellular carci-nogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 4753.
  • 4
    Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 797801.
  • 5
    Calvet X, Bruix J, Ginés P, Brú C, Sole M, Vilana R, Rodes J. Prognostic factors of hepatocellular carcinoma in the West. A multivariate analysis in 206 patients. Hepatology 1990; 12: 753760.
  • 6
    Makuuchi M. Surgical treatment for hepatocellular carcinoma. In: Ar-royoV, RodesJ, BoschJ, eds. Treatments in Hepatology. Barcelona: Mason, 1995: 341352.
  • 7
    Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, Visa J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterol-ogy 1996; 111: 10181023.
  • 8
    Franco D, Capussotti L, Smajda C, Bouzari H, Meakins J, Kemeny F, Grange D, et al. Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. Gastroenterology 1990; 98: 733738.
  • 9
    Fuster J, Garcia-Valdecasas JC, Grande L, Tabet J, Bruix J, Anglada T, Taura P, et al. Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. Ann Surg 1996; 223: 297302.
  • 10
    Nagasue N, Galizia G, Kohno H, Chang YC, Hayashi T, Yamanoi A, Nakamura T, et al. Adverse effects of preoperative hepatic artery che-moembolization for resectable hepatocellular carcinoma: a retrospective comparison of 138 liver resections. Surgery 1989; 106: 8186.
  • 11
    Pichlmayr R, Weimann A, Ringe B. Indications for liver transplantation in hepatobiliary malignancy. Hepatology 1994; 20: 33S40S.
  • 12
    McPeake JR, O'Grady JG, Zaman S, Portmann B, Wight DG, Tan KG, Calne RY, et al. Liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcome. J Hepatol 1993; 18: 226234.
  • 13
    Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693699.
  • 14
    Llovet JM, Bruix J, Fuster J, and the Liver Transplantation Unit. Liver transplantation for hepatocellular carcinoma. Results of a restrictive policy. Hepatology 1996; 24: 350A.
  • 15
    Boix L, Bruix J, Castells A, Vianney A, Llovet JM, Rivera F, Rodes J. Circulating mRNA for alpha-fetoprotein in patients with hepatocellular carcinoma. Evidence of tumor dissemination after transarterial emboli-zation [Abstract]. Hepatology 1996; 24: 349A.
  • 16
    Samuel D, Feray C, Bismuth H. Liver transplantation for chronic viral hepatitis. In: ArroyoV, RodesJ, BoschJ, eds. Treatments in Hepatology. Barcelona: Mason, 1995: 341352.
  • 17
    Shiina S, Tagawa K, Unuma T, Terano A. Percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma. AJR 1990; 154: 947951.
  • 18
    Vilana R, Bruix J, Bru C, Ayuso MC, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992; 16: 353357.
  • 19
    Ohnishi K, Nomura F, Ito S, Fujiwara -K. Prognosis of small hepatocellular carcinoma (less than 3 cm) after percutaneous acetic acid injection: study of 91 cases. Hepatology 1996; 23: 9941002.
  • 20
    Honda N, Guo Q, Uchida H, Ohishi H, Hiasa Y. Percutaneous hot saline injection therapy for hepatic tumors: an alternative to percutanoeus ethanol injection therapy. Radiology 1994; 190: 5357.
  • 21
    Seki T, Wakabayashi M, Nakagawa T, Itho T, Shiro T, Kunieda K, Sato M, et al. Ultrasonic ally guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994; 74: 817825.
  • 22
    Castells A, Bruix J, Brú C, Fuster J, Vilana R, Navasa M, Ayuso MC, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993; 18: 11211126.
  • 23
    Mondazzi L, Bottelli R, Brambilla G, Rampoldi A, Rezakovic I, Zavaglia C, Albert A, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology 1994; 19: 1151123.
  • 24
    Bruix J, Castells A, Montanya X, Calvet X, Bru C, Ayuso MC, Jover L, et al. Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology 1994; 20: 643650.
  • 25
    Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, Kawarada Y, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma-a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin. Cancer Chemother Pharmacol 1992; 31: S1S6.
  • 26
    Groupe d'Etude et de Traitament du carcinoma hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 12941296.
  • 27
    Harris CC, Hollstein M. Clinical implications of the p53 tumor supres-sor gene. N Engl J Med 1993; 329: 13181327.
  • 28
    Kalayci C, Johnson PJ, Raby N, Metivier EM, Williams R. Intraarterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin. J Hepatol 1990; 11: 349353.
  • 29
    Manesis EK, Giannoulis G, Zomboulis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 1995; 21: 15351542.
  • 30
    Boix L, Castells A, Bruix J, Sole M, Bru C, Fuster J, Rivera F, et al. Androgen receptors in hepatocellular carcinoma: relationship with tumor size and recurrence rate after surgical resection. J Hepatol 1995; 22: 616622.
  • 31
    Farinati F, Salvagnini M, de Maria N, Fornasieri A, Chiaramonte M, Rossaro L, Naccarato R. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol 1990; 12: 297301.
  • 32
    Martinez-Cerezo F, Tomas A, Donoso L, Enriquez J, Guarner C, Balanzo J, Martinez A, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994; 20: 702706.
  • 33
    Castells A, Bruix J, Bru C, Ayuso MC, Roca M, Boix L, Vilana R, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109: 917922.
  • 34
    Takara K, Ohto M, Yoshikawa M, Ebara M, Okuda K, Itami J, Arimizu N. Clinical and pathological study of irradiation therapy in 24 patients with hepatocellular carcinoma. Jpn J Gastroenterol 1986; 83: 14731482.
  • 35
    Matsuzaki Y, Osuga T, Saito Y, Chuganji Y, Tanaka N, Shoda J, Tsuji H, et al. A new, effective and safe therapeutic option using proton irradiation for hepatocellular carcinoma. Gastroenterology 1994; 106: 10321041.
  • 36
    Raoul JL, Guyader D, Bretagne JF, Duvauferrier R, Bourguet P, Bek-hechi D, Deugnier YM, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35: 17821787.
  • 37
    Lai CL, Lau JYN, Wu PC, Ngan H, Chung HT, Mitchell SJ, Corbett TJ, et al. Recombinant interferon alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17: 389394.